September 10, 2024 07:07 AM EDTUpdated 07:55 AM
R&D

Centes­sa to take nar­colep­sy drug in­to Phase 2 af­ter no sign of side ef­fects that doomed ear­li­er com­peti­tor

Drew Armstrong

Executive Editor

Centes­sa Phar­ma­ceu­ti­cals plans to take its orex­in re­cep­tor 2 ag­o­nist in­to mid-stage test­ing for nar­colep­sy af­ter a Phase 1 study showed signs of ef­fi­ca­cy. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times